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Abstract: 
 
Nanoparticle (NP)‐based drug‐delivery systems are frequently employed to improve the 
intravenous administration of chemotherapy; however, few reports explore their application as an 
intraperitoneal therapy. We developed a pH‐responsive expansile nanoparticle (eNP) specifically 
designed to leverage the intraperitoneal route of administration to treat intraperitoneal 
malignancies, such as mesothelioma, ovarian, and pancreatic carcinomatoses. This review 
describes the design, evaluation, and evolution of the eNP technology and, specifically, 
a Materials‐Based Targeting paradigm that is unique among the many active‐ and passive‐
targeting strategies currently employed by NP‐delivery systems. pH‐responsive eNP swelling is 
responsible for the extended residence at the target tumor site as well as the subsequent 
improvement in tumoral drug delivery and efficacy observed with paclitaxel‐loaded eNPs (PTX‐
eNPs) compared to the standard clinical formulation of paclitaxel, Taxol®. Superior PTX‐eNP 
efficacy is demonstrated in two different orthotopic models of peritoneal cancer—mesothelioma 
and ovarian cancer; in a third model—of pancreatic cancer—PTX‐eNPs demonstrated 
comparable efficacy to Taxol with reduced toxicity. Furthermore, the unique structural and 
responsive characteristics of eNPs enable them to be used in three additional treatment 
paradigms, including: treatment of lymphatic metastases in breast cancer; use as a highly 
fluorescent probe to visually guide the resection of peritoneal implants; and, in a two‐step 
delivery paradigm for concentrating separately administered NP and drug at a target site. This 
case study serves as an important example of using the targeted disease‐state's pathophysiology 
to inform the NP design as well as the method of use of the delivery system.  
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Article: 
 
INTRODUCTION 
 
In this review, we describe the design, evaluation, and evolution of the expansile nanoparticle 
(eNP) technology—a drug‐delivery system specifically designed for the treatment of 
intraperitoneal malignancies. We highlight the challenges of treating intraperitoneal cancers and 
summarize the state‐of‐the art in both clinical treatments and novel therapies. We describe how 
this technology leverages the pathophysiology of peritoneal tumors to enable a new type 
of Materials‐Based Targeting strategy along with an efficient high‐dose delivery of 
chemotherapy, both of which involve pH‐triggered particle swelling—a keystone of the eNPs’ 
function and mechanism of action. We highlight the rigorous nanoparticle characterization and 
testing required to validate particle function and describe the efficacy of paclitaxel‐loaded eNPs 
(PTX‐eNPs) in three different models of peritoneal cancer: mesothelioma, ovarian, and 
pancreatic carcinomatosis (i.e., cancer spread throughout the peritoneal cavity). Lastly, we 
describe the structural and responsive characteristics of eNPs that enable the technology to be 
uniquely leveraged in three additional treatment paradigms: as a means of treating lymphatic 
spread of disease (i.e., regional metastases); as a highly fluorescent probe to visually guide 
surgical resection of peritoneal implants and small tumors; and, as a two‐step drug‐delivery 
device for concentrating separately administered drug at a target site. 
 
Current treatments for patients with peritoneal malignancies frequently involve a complex 
combination of cytoreductive surgery, to remove large bulky disease, and peri‐ or post‐operative 
administration of chemotherapy to treat residual, un‐resected, or occult disease. Even though 
residual disease is located within the peritoneal cavity in the vast majority of patients, most 
chemotherapeutic regimens are administered intravenously. Intravenous administration leads to 
poor tumoral delivery with, frequently, less than 1% of the injected dose accumulating in tumors 
due to systemic distribution and rapid first‐pass clearance.1 In contrast, drugs that are 
administered via the intraperitoneal route of administration are maintained in close proximity to 
the target tumor tissues leading to more rapid and prolonged tumoral accumulation and increased 
efficacy compared to intravenous administration.2-5 
 
Recent clinical studies demonstrate the benefit of intraperitoneal delivery. The results of two 
Gynecologic Oncology Group studies (GOG‐0114 and GOG‐0172) conclusively demonstrated 
improved outcomes for ovarian cancer patients treated with intraperitoneal Taxol® (Box 1) 
+ cisplatin as opposed to standard intravenous injections of the same combination (overall 
survival of 61.8 months versus 51.4 months, 23% decreased risk of death).6 Intraperitoneal 
delivery is also being investigated in peritoneal carcinomatosis of pancreatic ductal 
adenocarcinoma origin (PDAC‐PC) where several clinical trials are ongoing.7-9 In patients with 
malignant peritoneal mesothelioma, observational studies document a similar improvement in 
patient survival for those undergoing cytoreductive surgery in combination with intraperitoneal 
chemotherapy (e.g., Taxol + cisplatin).2, 5 While no Phase III randomized clinical trials have been 
performed due to the limited number of patients presenting with peritoneal mesothelioma in the 
U.S., there is discussion that these combined surgical/chemotherapeutic regimens lead to 
improved outcomes. These conclusions must be handled with caution since, in the absence of 
randomized clinical trials, evaluation may be skewed by confounding variables or from referral 
bias due to patient selection favoring those with earlier‐stage disease and fewer co‐morbidities 
who are likely to have better outcomes. Unfortunately, randomized clinical trials may become 
possible in the future as the worldwide incidence of mesothelioma continues to rise with 
continued use of asbestos as an insulating material in the developing world.10, 11 
 
BOX 1. DEFINITIONS 
PTX = paclitaxel (the drug alone) 
PTX‐eNP = paclitaxel‐loaded expansile nanoparticle 
Taxol® = paclitaxel dissolved in Cremophor EL/ethanol (i.e., the clinical formulation of 
paclitaxel) 
 
Despite the benefits to be gained from intraperitoneal administration, significant drawbacks have 
hampered the adoption and implementation of this treatment strategy. Primary among these are 
the heightened risk of systemic toxicity, surgical wound healing, and technical complexity 
associated with intraoperative circulation of chemotherapy.1, 12, 13 While intraperitoneal 
administration improves the pharmacokinetic profile of higher molecular weight (MW) agents 
(e.g., PTX, MW = 853.9 g/mol) compared to intravenous administration with a t ½ of 3–
7 h,14, 15 systemic clearance is nevertheless still rapid with plasma t ½ on the order of 4–12 h for 
intraperitoneal administration.4 
 
In addition, the large surface area of the peritoneal cavity, widespread dissemination of 
peritoneal tumors, and the presence of microtumors resulting from dissemination and seeding of 
tumors throughout the peritoneal cavity,16, 17 make complete surgical resection both a herculean 
effort and one that is rarely achieved. Lastly, peritoneal tumors can be inoperable due to 
proximity to vital organs and structures. As a consequence of incomplete surgical resection, 
intraoperative tumor‐cell seeding, or growth of occult microtumors, the majority of patients 
eventually develop recurrent disease that is typically more aggressive, frequently inoperable, and 
less responsive to chemotherapy/radiation therapy.18 It is the local progression of peritoneal 
disease, rather than metastatic disease, that results in the poor 5‐year survival rates associated 
with mesothelioma and ovarian cancer.19, 20 In resectable pancreatic cancer, the stagnant, 5‐year 
survival rate remains low due to recurrence or metastases, with 50% of patients presenting with 
peritoneal metastases.21 
 
We identified the above challenges as a significant clinical opportunity that could be addressed 
by the development of a nanoparticle‐based drug‐delivery system for administration via the 
intraperitoneal route. The intraperitoneal route of administration has been leveraged by others 
developing nanoparticle‐based drug‐delivery systems22-26 and is in contrast to the majority of 
nanoparticle systems, which are currently designed for intravenous administration.27-32 
Specifically, we identified five design requirements necessary for the success of such a system, 
including the ability to: (1) leverage the intraperitoneal route of administration for peritoneal 
malignancies; (2) deliver a clinically relevant chemotherapeutic agent; (3) preferentially localize 
to tumor tissue through a unique Materials‐Based Targeting mechanism that does not rely on the 
use of passive [i.e., enhanced permeability and retention (EPR) effect] or active (i.e., antibody‐
based) targeting; (4) respond to a physiological cue to release its payload only at the target site 
thereby minimizing off‐target side effects and toxicity; and, (5) provide prolonged (days to 
weeks) delivery of therapeutic concentrations of drug and thereby improve treatment efficacy as 
measured by quantitative clinical endpoints (e.g., tumor growth or overall survival). To fulfil 
these design requirements and address this challenge, we engineered the eNP‐delivery system 
(Figure 1). 
 
 
Figure 1. Schematic of expansile nanoparticle (eNP)‐mediated drug delivery to peritoneal 
tumors. eNPs are administered intraperitoneally and localize to tumors via Materials‐Based 
Targeting. Disruption of intracellular trafficking results in eNP accumulation and delivery of 
high concentrations of paclitaxel (PTX) to the target cell. 
 
DESIGN AND CHARACTERIZATION OF THE eNP SYSTEM 
 
The essential and unique material properties of the eNPs are derived from their polymer 
structure. Each eNP monomer unit is composed of three basic building blocks: (1) a 
hydrophobic, pH‐responsive protecting group that masks, (2) a hydrophilic triol‐linker, and (3) a 
methyl methacrylate end‐group that enables polymerization (Figure 2(a)).33 Incorporation of a 
small percentage of a hydroquinone‐based di‐ester methacrylate leads to crosslinking of the 
polymer chains. The hydrophobicity imparted by the protecting group allows the monomer to be 
dissolved in organic solvents (e.g., dichloromethane, ethyl acetate). This, in turn, enables 
synthesis of nanoparticles via formation of an oil‐in‐water emulsion followed by in 
situ polymerization of the monomer and crosslinker. The oil‐in‐water synthetic scheme also 
enables loading of hydrophobic drug payloads, such as the small molecule chemotherapeutic 
PTX, which partitions into the oil/eNP phase. Following polymerization, particles are stirred 
under air to allow the evaporation of the organic solvent and dialyzed in pH 7.4 phosphate buffer 
to remove excess salts and surfactants. The eNPs are stabilized with an anionic sodium dodecyl 
sulfate surface coating that imparts a strong negative surface charge (−30 to −50 mV). The 
resultant particles possess a smooth morphology and a mean diameter of 30–50 nm as visualized 
by scanning electron microscopy (SEM). 
 
 
FIGURE 2 IS OMITTED FROM THIS FORMATTED DOCUMENT 
Figure 2. (a) Schematic of the expansile nanoparticle (eNP) and non‐expansile nanoparticle 
(neNP) chemical structures and function. (b) Hydrolysis of the eNP and neNP protecting groups 
as a function of time under pH 5 and pH 7.4 conditions. (c) Hydrophobicity of the eNP as a 
function of time in swelling particles (pH 5) and unswollen particles (pH 7.4). (d–f) 
Transmission, freeze‐fracture transmission, and scanning electron micrographs of unswollen 
eNPs at pH 7.4 and swollen eNPs at pH 5. A decrease in eNP density (opacity in d) and increase 
in eNP size (e, f) are readily apparent. (g) eNP swelling and neNP lack‐of swelling is 
characterized via dynamic light scattering at pH 5 and 7.4. (h) Particle‐by‐particle swelling of 
eNPs incubated at pH 5 is observed using scanning ion occlusion sensing (qNano) technology. 
(Reprinted with permission from Ref 33. Copyright 2009 American Chemical Society; Ref 34. 
Copyright 2013 They Royal Society of Chemistry) 
 
The eNP's lightly crosslinked polymer structure affords a pH‐triggered swelling functionality. 
Specifically, the pH‐labile, 2,4,6‐trimethoxybenzilidene acetal‐protecting group is stable at 
pH 7.4 but hydrolyzes slowly at pH 6 and faster at mildly acidic pH ~5; this deprotection is 
readily monitored via high‐performance liquid chromatography (HPLC; Figure 2(b)).33 As a 
consequence, when eNPs reach the extracellular environment of microscopic hypoxic 
tumors,35 large hypoxic tumors36 (pH ~6.5) or the late endosomal/lysosomal compartments of 
tumor cells (pH ~5), the protecting group hydrolyzes, exposing the more hydrophilic alcohol 
moieties. Hydrolysis of the ester linkage between the polymer backbone and linker is slower than 
the release of the protecting group given that the former is an ester and the latter is an activated 
acetal. If minimal hydrolysis of the ester linkage between the polymer backbone and linker 
occurs, it would result in exposure of a hydrophilic carboxylic acid moiety instead of two 
hydrophilic hydroxyls. A corresponding change in the hydrophobicity of the eNPs can be 
monitored via covalent incorporation of pyrene‐methyl methacrylate—a solvochromatic dye 
whose fluorescence emission spectrum reflects the polarity of the surrounding environment 
(Figure 2(c)).34 This compositional change from hydrophobic to hydrophilic leads to water 
infiltration into the polymer network and swelling of the particle. Particles swell, but do not 
immediately degrade as a result of the light (1% wt/wt) crosslinking. Particle swelling can be 
visualized via electron microscopy including, transmission‐, freeze‐fracture transmission‐, and 
SEM (Figure 2(d)–(f)).33, 34, 37, 38 To complement these techniques, dynamic light scattering and 
tunable resistive pulse‐sensing (i.e., qNano technology from iZon Ltd.) which provides the added 
benefit of measuring particle concentration, are also used (Figure 2(g) and (h)).33, 34, 39 In these 
‘aqueous’ studies, the particles swell, and the density and mechanical modulus of the particles 
decreases with the terminal state of swelling being dissolution of the particle into individual 
polymer chains.34, 40 Furthermore, these studies, which examine swelling over various time 
courses and under multiple pH and buffering conditions, reveal that eNP swelling is a 
heterogeneous process that occurs over a time‐scale of hours to days and with an ultimate 
increase in particle diameter on the order of 2–10X. 
 
Particle swelling plays a critical role in the drug‐release kinetics of the eNP system. Specifically, 
drug is packaged securely within the eNP as long as the pH of the local environment remains 
neutral and the particle unswollen. Upon acidification, the eNP swells and the encapsulated drug 
payload is released slowly over a period of time that closely mirrors the time‐course of polymer 
deprotection and particle swelling (Figure 3).33 Three different control particles were employed 
to confirm the pH‐responsive drug‐release functionality. First, substituting benzaldehyde for the 
protecting group (Figure 2(a)) increased the stability of the structure, preventing hydrolysis at 
pH 5–6.5 and necessitating exposure to strongly acidic conditions (pH ≤2) to induce deprotection 
and swelling. Particles with this structure are termed ‘non‐expansile nanoparticles’ (neNPs) and 
serve as a chemically similar functional control under mildly acidic (pH 5–6.5) conditions. As a 
result, drug release from neNPs is independent of pH (Figure 3).33 Second, eNPs were 
synthesized with ‘heavy’ crosslinking (30% wt/wt versus the ‘standard’ 1% wt/wt; termed ‘30X‐
eNPs’). Unlike the neNPs, the 30X‐eNPs still undergo hydrolysis at pH 5, however the increased 
crosslinking prevents swelling and release of the drug payload thereby confirming that 
deprotection of the polymer alone is not enough to induce drug release (Figure 3).38 Third, non‐
responsive, generic PTX‐loaded poly(lactic‐co‐glycolic) acid nanoparticles (PTX‐PLGA‐NPs) 
demonstrated rapid ‘burst’ release within the first 4 h regardless of pH. 
 
FIGURE 3 IS OMITTED FROM THIS FORMATTED DOCUMENT 
Figure 3. Paclitaxel (PTX) release from expansile nanoparticle (eNPs) is characterized by high‐
performance liquid chromatography (HPLC) at pH 5 and pH 7.4. eNPs release PTX in a pH‐ and 
time‐dependent manner. Control non‐expansile nanoparticles (neNPs) and poly(lactic‐co‐
glycolic) acid (PLGA)‐NPs exhibit burst release regardless of pH. Control heavily crosslinked‐
eNPs (30X‐eNPs) do not exhibit pH‐dependent release. (Reprinted with permission from Ref 33. 
Copyright 2009 American Chemical Society; Ref 38. Copyright 2016 Future Medicine Ltd.) 
 
FIGURE 4 IS OMITTED FROM THIS FORMATTED DOCUMENT 
Figure 4. Materials‐Based Targeting. (a) Confocal microscopy demonstrates that expansile 
nanoparticle (eNPs) localize to late endosomes/lysosomes in vitro. (b) Pharmacologic inhibition 
of eNP uptake demonstrates that macropinocytosis is the primary pathway of particle 
internalization. (c) Schematic of proposed intracellular action of eNPs leading to prolonged 
tumoral accumulation. (d) Quantification of LC3‐II in MSTO‐211H mesothelioma tumor cells 
demonstrates dose‐dependent increases when treated with eNPs. (e) Fluorescently labelled eNPs 
(blue/white) accumulate specifically within regions of intraperitoneal tumor (white dashed 
circles) and remain for at least 2 weeks. (f) eNP internalization into malignant tumor cells in 
vitro is an order of magnitude faster than in healthy epithelial cells. (Reprinted with permission 
from Ref 42. Copyright 2013 American Chemical Society; Ref 43. Copyright 2016 Elsevier 
B.V.) 
 
Particle swelling also plays an important role in the mechanistic interplay between the eNP and 
the sub‐cellular trafficking that occurs following internalization within a cell. Prolonged 
intracellular accumulation of eNPs is essential to their efficacy because the drug payload, PTX, 
must be present at therapeutic concentrations within the cell for at least one cell‐cycle (i.e., 
>20 h) to be cytotoxic.41 Based on the results generated with pharmacological inhibitors, 
temperature‐sensitive metabolic reduction and fluid‐phase marker co‐localization of 
fluorescently labeled eNPs (Figure 4(a)), macropinocytosis is the primary pathway of particle 
uptake in multiple cancer cell lines, including: mesothelioma (MSTO‐211H) and triple‐negative 
(i.e., ER‐, PR‐, Her2/neu‐) breast carcinoma (MDA‐MB‐231) (Figure 4(b)).42, 43 A similar uptake 
pathway is found with mesothelioma spheroids, which provide a measure of improved modeling 
of the tumoral microenvironment, including a collagen extracellular matrix.44 Following 
internalization, eNPs disrupt sub‐cellular trafficking, leading to a block in autophagic flux and 
prolonged particle accumulation.43 
 
The exact mechanism by which eNPs interfere with sub‐cellular trafficking is still being 
investigated, but control experiments demonstrate that it is likely linked to the swelling 
functionality of eNPs (Figure 4(c)). Specifically, while treatment with eNPs led to dose‐
dependent increases in LC3‐II—a protein sequestered in the membranes of autophagosomes and 
whose accumulation serves as a marker of the impairment of autophagy—treatment with PLGA‐
NPs had no significant effect (Figure 4(d)). Furthermore, treatment with eNPs also inhibited 
autophagosomal degradation and flux as measured by accumulation of p62—a protein normally 
degraded during autophagy. Treatment with PLGA‐NPs or neNPs did not inhibit 
autophagosomal degradation/flux.43 Though these control studies are not exhaustive, they 
suggest the centrality of swelling in achieving prolonged intracellular accumulation via 
disruption of sub‐cellular trafficking. These results provide impetus for the development of new 
delivery systems specifically designed to optimize the disruption of particle trafficking as a 
stand‐alone therapeutic strategy or as part of a more complex treatment scheme. 
 
BOX 2. MATERIALS‐BASED TARGETING 
leverages the rapid metabolism of tumor cells compared to healthy cells as well as 
nanoparticle swelling that, following internalization, disrupts sub‐cellular trafficking to 
achieve accumulation of particles within the target tumor cells. Materials‐Based Targeting 
stands in contrast to both passive‐targeting strategies that rely upon the enhanced permeability 
and retention (EPR) effect as well as active‐targeting strategies that rely upon the use of 
targeting moieties such as antibodies, oligonucleotides, or other complementary high‐affinity 
probes (e.g., biotin‐avidin). 
 
eNP swelling, and the ensuing disruption of sub‐cellular trafficking, is integral to the in 
vivoperformance of eNPs. To visually assess the tumoral accumulation of eNPs, particles were 
covalently labeled with a fluorophore [either PolyFluor407 (PF‐eNPs) or rhodamine‐methyl 
methacrylate (Rho‐eNPs)] and administered to mice bearing established intraperitoneal 
mesothelioma tumors. PF‐eNPs localize rapidly, within 4 h of injection, to regions of tumor of 
varying sizes from sub‐mm to sub‐cm and ≥1 cm. Furthermore, particles persist in the tumors for 
at least 14 days (Figure 4(e)).43 In contrast, neither rhodamine‐labeled PLGA‐NPs, neNPs nor 
PEG‐ylated eNPs are observable within tumors 24 h after injection.43, 45 To investigate the 
mechanism behind this localization, we evaluated the in vitro uptake of Rho‐eNPs in both 
healthy, non‐immortalized, mesothelial cells (LP‐3) and malignant mesothelioma cells (MSTO‐
211H) using flow assisted cell sorting. Tumor cells internalize Rho‐eNPs an order of magnitude 
faster than healthy cells (98% uptake versus 2% uptake after 2 h of incubation, respectively) 
(Figure 4(f)), which is consistent with the well‐documented hyper‐function of endosomal 
processes in tumor cells that leads to increased rates of endocytosis.43, 46 Notably, eNPs 
demonstrate this rapid, highly specific and prolonged tumoral accumulation without the use of 
targeting ligands, antibodies, or external triggers (e.g., light, sound, heat). With control 
experiments demonstrating that the material properties of the eNP polymer (i.e., pH‐triggered 
swelling) are an essential design requirement to achieve tumoral accumulation, rather than 
surface functionalization, we have termed the ‘targeting’ observed with eNPs: ‘Materials‐Based 
Targeting’ (Box 2). This stands in contrast to both passive‐targeting strategies that rely upon the 
enhanced permeability and retention (EPR) effect as well as active‐targeting strategies that rely 
upon the use of targeting moieties such as antibodies, oligonucleotides or other complementary, 
high‐affinity probes (e.g., biotin‐avidin). 
 
eNPs IN INTRAPERITONEAL MESOTHELIOMA 
 
With the Materials‐Based Targeting strategy providing tumor‐specific accumulation of eNPs, we 
hypothesized that intraperitoneal administration of PTX‐eNPs would provide prolonged tumoral 
and target‐specific drug delivery. To determine the pharmacokinetic profile of PTX delivered via 
eNPs, animals with established intraperitoneal mesothelioma tumors were treated with a single 
intraperitoneal injection of PTX‐eNPs. Animals were euthanized at various time points out to 7 
days post‐injection, and PTX concentration in the tumors, plasma, and a peritoneal lavage 
performed at the time of euthanasia was quantified by HPLC‐mass spectrometry (HPLC‐MS). 
As a control, a second group of animals received ‘free’ PTX dissolved in Cremophor EL/ethanol 
(i.e., the clinically used formulation of PTX; Taxol®). Both groups were given the equivalent of 
10 mg/kg PTX which, when scaled by body surface area, is somewhat lower than a standard 
135 mg/m2 dose used clinically in humans. Treatment with PTX‐eNPs increased the intratumoral 
delivery of PTX by 10‐fold compared to Taxol over the first 24 h and by over 100‐fold compared 
to Taxol 7 days following the injection (Figure 5(a)).43 Maintenance of these high, super‐
therapeutic concentrations of PTX is significant because it is well‐documented that treatment 
with low doses of PTX at concentrations below the IC50 of ~10–50 ng/mL may drive the 
development of drug resistance.41, 47, 48 While the comparison of PTX per mass of tissue in 
vivo and the in vitroIC50 is not exact, it is nevertheless clear that eNPs deliver PTX to the target 
tissue at concentrations in excess of 10,000‐fold the IC50. Due to the rapid clearance of PTX 
administered as Taxol within the first 4 h, PTX concentrations in the plasma and peritoneal 
lavage are higher when delivered as PTX‐eNPs than Taxol at all time points after the first 4 h. 
This is reflective of two factors: first, the prolonged accumulation of PTX within the tumors 
establishes, in effect, a ‘drug depot’ that continues to elute PTX into the surrounding tissues and, 
subsequently, the plasma for at least 7 days; second, the intraperitoneal administration of Taxol 
results in a bolus of drug which diffuses from the peritoneal cavity into the plasma and is rapidly 
cleared with greater than 99% of the drug removed within the first 24 h. To compare the eNP 
system against a generic, non‐responsive nanoparticle control, the experiment was also run with 
PTX‐PLGA‐NPs and the intratumoral concentration of PTX was demonstrated to be <20% of 
that achieved via the PTX‐eNP.43 
 
FIGURE 5 IS OMITTED FROM THIS FORMATTED DOCUMENT 
Figure 5. (a) Pharmacokinetics of paclitaxel (PTX) administered via expansile nanoparticle 
(eNPs) or as Taxol. Paclitaxel‐loaded eNPs (PTX‐eNPs) deliver 10‐ to 100‐fold more PTX to 
intraperitoneal mesothelioma tumors than is achieved with Taxol. (b) In a multi‐dose established 
disease model, PTX‐eNPs significantly improve survival compared to all controls and 33% of 
animals demonstrate a complete clinical response. (c) Doubling the weekly dose of PTX‐eNPs or 
Taxol to 20 mg/kg/week does not improve survival compared to the 10 mg/kg/week dose. (d) 
Doubling the duration of dosing from 4 to 8 weeks increases overall survival of PTX‐eNP‐
treated animals while providing no benefit to Taxol‐treated animals. (Reprinted with permission 
from Ref 43. Copyright 2013 Elsevier B.V.) 
 
With the improvements in tumoral drug delivery observed using PTX‐eNPs as compared to 
Taxol, we hypothesized that intraperitoneal administration of PTX‐eNPs would significantly 
improve overall survival in intraperitoneal mesothelioma. In a model of established disease, 
animals received four weekly intraperitoneal treatments of PTX‐eNPs or Taxol (10 mg/kg), 
which was designed to mimic the multi‐dose regimens clinically employed to treat mesothelioma 
in patients. Additional control groups included: unloaded‐eNPs (vehicle control); PTX‐loaded 
PLGA‐NPs (PTX‐PLGA‐NPs; non‐swelling, generic NP control); unloaded‐PLGA‐NPs (PLGA 
vehicle control); and saline (tumor growth control). The PTX‐eNP group demonstrated a 
significant improvement in survival versus all controls and a >50% increase in median survival 
compared to Taxol (72 days versus 46 days, respectively). Remarkably, ~30% of animals 
demonstrated a complete clinical response during the study (Figure 5(b)).43 The Taxol group 
experienced a modest improvement in median survival versus saline (46 days versus 38 days) 
consistent with the improvements observed clinically in patients treated with intraperitoneal 
Taxol. PTX delivery via PLGA‐NPs afforded no improvement over Taxol (median survival 43 
days) and we interpreted this to be the result of: (1) lack of tumor‐specific accumulation—
PLGA‐NPs do not accumulate significantly in tumors;43, 45, 49 and, subsequently, (2) non‐tumor‐
specific delivery of PTX resulting in sub‐therapeutic tumor‐tissue concentrations. 
 
To determine whether the improvement in animal survival afforded by multiple PTX‐eNP 
treatments could be increased further, two additional studies were conducted. First, the 
treatment‐of‐established disease model was repeated with the exception that animals received 
double the weekly dose of PTX (i.e., 4‐weekly injections of 20 mg/kg). Interestingly, doubling 
the dose resulted in no measureable improvement to animal survival compared to the 10 mg/kg 
treatment (Figure 5(c)).43 This indicated that dose was not the limiting factor and that, rather, 
duration of drug exposure was the key element in improving mortality. Therefore, a second study 
was conducted to evaluate the impact of doubling the duration of treatment from the initial 4‐
week study (i.e., 8‐weekly injections of 10 mg/kg). Median survival of the PTX‐eNP treated 
group was prolonged to 103 days, an increase of over 43% compared to the 4‐week PTX‐eNP 
(72 days) and an increase of over 110% compared to the 8‐week Taxol group (49 days) 
(Figure 5(d)).42 Importantly, all but one of the animals receiving Taxol died or were euthanized 
due to morbidity, according to IACUC guidelines, before completing their 8‐week treatment 
regimen reflecting the underlying failure of standard Taxol alone to effectively deliver drug to 
the tumor despite a chronic dosing regimen. Together, these results demonstrate that, contrary to 
the clinical impression that mesothelioma is ‘PTX resistant,’ which the Taxol data would 
support, PTX is an effective treatment for intraperitoneal mesothelioma if its pharmacokinetic 
profile is properly tailored via the use of a delivery system, such as the eNP. 
 
eNPs IN OVARIAN CANCER 
 
In addition to treating mesothelioma, intraperitoneal administration of PTX is employed 
clinically to treat ovarian cancer. A recent clinical trial demonstrated that ovarian cancer patients 
who underwent cytoreductive surgery and received multiple intraperitoneal boluses of Taxol 
demonstrated a 23% increase in survival over 10 years compared to patients who received 
traditional IV Taxol therapy.50 These results further validate the benefit gained by leveraging the 
proximity of drug to tumor inherent in the intraperitoneal route of administration, and it may be 
expected that further improvements to the current PTX formulation may afford greater tumor‐
specific delivery and a wider therapeutic window resulting in improved patient outcomes. For 
example, Taxol's toxicity and high complication rate lead to more than 58% of patients with 
advanced ovarian cancer being unable to complete a standard course of intraperitoneal therapy 
due to peritoneal adhesions, bowel obstructions, infections, and catheter‐related complications.51-
54 We therefore hypothesized that the PTX‐eNP technology would provide a significant 
improvement over the standard of care in an ovarian cancer model by specifically targeting 
tumor tissue and locally delivering PTX. 
 
To evaluate PTX‐eNPs in ovarian cancer, a series of in vitro and in vivo assays were 
employed. In vitro cell cytotoxicity assays demonstrated comparable efficacy between PTX‐
eNPs and Taxol in an immortalized OVCAR‐3 cell line (Figure 6(a)). In contrast, PTX‐eNPs 
were significantly more cytotoxic than Taxol in fresh human ovarian cancer cells derived from 
the malignant pleural effusion of a multidrug‐resistance patient (Figure 6(b)).55 We hypothesize 
that the increased efficacy of PTX‐eNPs in drug resistant cells may be due to the establishment 
of a PTX ‘drug depot’ within the tumor cells. Internalization of PTX‐eNPs establishes an 
intracellular source of PTX that overcomes the PTX‐efflux initiated by cell‐membrane proteins, 
such as ABC‐transporters, involved in multi‐drug resistance.56 Additional studies are ongoing to 
investigate the ability of eNPs to overcome drug resistance. In in vitro cell‐uptake assays, eNPs 
demonstrated similarly rapid rates of internalization into malignant ovarian cancer cells as was 
previously observed in the mesothelioma model.43, 55 Again, similar to the mesothelioma model, 
tumor‐specific accumulation of fluorescently labeled eNPs was observed in vivo in established 
ovarian tumors (Figure 6(c)).55 To simulate the clinical scenario of tumor‐resection followed by 
intraperitoneal chemotherapy, we developed a resection‐based ovarian cancer model in which 
animals were xenografted and bulky tumor was allowed to develop over a 4‐week period. 
Animals underwent intraoperative debulking to remove intraperitoneal tumors with >95% having 
<3 mm tumors remaining with an operative mortality of <10%. Following debulking, animals 
received intraperitoneal injections of either PTX‐eNPs (experimental; 10 mg/kg), Taxol 
(clinically used control; 10 mg/kg), or unloaded‐eNPs (vehicle control). Animals were 
euthanized 4 weeks later, when the control group (unloaded‐eNP) developed sufficient tumor to 
require euthanasia according to IACUC guidelines. Treatment with PTX‐eNPs resulted in a 
profound decrease in the degree of tumor recurrence as compared to treatment with Taxol (0% 
versus 40%, respectively) (Figure 6(d)).55 The results of this ovarian cancer study validated the 
efficacy of PTX‐eNPs in a second intraperitoneal tumor model and demonstrated that the 
mechanistic driver for this efficacy—tumor‐specific localization of eNPs—is active in multiple 
cancer models. 
 
FIGURE 6 IS OMITTED FROM THIS FORMATTED DOCUMENT 
Figure 6. (a) Paclitaxel‐loaded eNPs (PTX‐eNPs) display equivalent cytotoxicity to Taxol in 
vitro against OVCAR‐3 breast cancer cells. (b) PTX‐eNPs are significantly (*P < 0.01) more 
cytotoxic than Taxol in multi‐drug resistant human ovarian cancer cells at concentrations greater 
than 10 ng/mL. (c) Fluorescent, rhodamine‐labelled‐eNPs (Rho‐eNPs) localize specifically to 
regions of intraperitoneal ovarian cancer. (d) PTX‐eNPs reduce the incidence of significant 
tumor recurrence (0%) in an orthotopic model of ovarian cancer compared to Taxol (40% 
significant recurrence). (Reprinted with permission from Ref 55. Copyright 2012 Society of 
Surgical Oncology) 
 
eNPs IN PANCREATIC CANCER 
 
Besides ovarian cancer and mesothelioma, intraperitoneal administration of chemotherapy is also 
used to treat pancreatic carcinomatosis and, similarly, we hypothesized that the eNP‐delivery 
system would demonstrate tumor‐specific behavior in this model. Recent reports57, 58 have 
highlighted the importance of cancer stem cells (CSCs) to tumor growth, invasion and 
metastasis, and drug resistance. We therefore developed a pancreatic carcinomatosis rat model 
using Panc‐1‐derived CSCs (Panc‐1‐CSCs) with the aim of recapitulating the aggressive and 
drug‐resistant phenotype frequently observed in pancreatic cancer.59 In vitro evaluation of 
fluorescently labeled eNPs demonstrated similar behavior as previously observed in ovarian and 
mesothelioma models with eNPs rapidly internalized into both Panc‐1 cells and Panc‐1‐CSCs 
within 1–4 h in vitro.38 To investigate the kinetics and dose‐dependence of eNP tumor 
localization in vivo, Rho‐eNPs were injected into animals bearing established Panc‐1‐CSC 
tumors and imaged 1, 4, and 24 h post‐injection. Dose‐titration studies revealed that 
intraperitoneal injection of 1 mL of Rho‐eNPs was the optimum dose to achieve maximum 
tumor‐specific fluorescence and this was used in the following kinetics study.38 As with the 
ovarian and mesothelioma models, tumor‐specific accumulation was observed within 4 h of 
injection (Figure 7(a)).38 Minimal tumoral localization was observed after 1 h with most particles 
still in the ascites fluid; after 4 h minimal eNP‐fluorescence was observed in the ascites fluid 
with the preponderance of fluorescence occurring in the tumors. Complete penetration into and 
throughout some, though not all, large tumors was observed (Figure 7(b)). 
 
FIGURE 7 IS OMITTED FROM THIS FORMATTED DOCUMENT 
Figure 7. (a) Fluorescent rhodamine‐labelled expansile nanoparticle (Rho‐eNPs; orange in UV 
light) localize to pancreatic tumors within 1–4 h of intraperitoneal injection. (b) Rho‐eNPs 
penetrate deep into and entirely throughout some tumors. (c) Paclitaxel‐loaded eNPs (PTX‐
eNPs) provide an equivalent survival benefit to Taxol in an orthotopic, cancer stem‐cell‐derived 
model of pancreatic cancer. PTX‐eNPs show a trend, though not significant, toward reduced 
tumor burden. (d) PTX‐eNPs demonstrate reduced toxicity, as quantified by duodenal wall 
thickness and diameter, compared to Taxol. (Reprinted with permission from Ref 38, Copyright 
2016 Future Medicine Ltd.) 
 
This study validated the principle of Materials‐Based Targeting in a third orthotopic model and 
was in concordance with the in vitro uptake models in malignant mesothelioma and ovarian 
cancer cell lines. It is important to note that the predictive power of in vitro assays must be 
handled with caution as not all particle formulations that demonstrate rapid in vitro uptake also 
demonstrate tumor‐specific localization.43 This is a reflection of the often one‐dimensional 
nature of in vitro assays, which can be a poor substitute for the multi‐dimensional, complex, and 
many‐faceted interactions of an in vivo system.60 
 
Based upon the highly specific tumoral accumulation observed in vivo, we expected that PTX‐
eNPs would be as efficacious in vivo as was observed in the ovarian and mesothelioma models. 
Animals were xenografted with Panc‐1‐CSCs and allowed 2 weeks for bulky tumors to establish. 
Treatments were then administered weekly for 4 weeks with all PTX groups receiving PTX at 
10 mg/kg. Treatments included: PTX‐eNPs (experimental), Taxol (clinical formulation control), 
unloaded‐eNPs (vehicle control), and saline (tumor growth control). While both PTX‐eNP and 
Taxol improved survival compared to the saline and unloaded‐eNP control groups, there was no 
significant difference in survival between PTX‐eNP and Taxol treatment groups. All animals 
were euthanized at day 50 post‐xenografting and quantification of tumor burden in the remaining 
animals revealed a trend, though not statistically significant, towards reduced tumor burden with 
the PTX‐eNPs as compared to Taxol (Figure 7(c)).38 Secondary endpoints, including in‐life 
activity and degree of cachexia, as quantified by muscle mass and gut size at sacrifice, 
demonstrated that the PTX‐eNP treatment resulted in significantly less toxicity and fewer side 
effects than Taxol (Figure 7(d)).38 
 
The differences in efficacy observed between the pancreatic, ovarian, and mesothelioma models 
are likely due to three factors. First, by using CSCs to establish the pancreatic xenografts, these 
tumors were inherently more aggressive and likely drug resistant, though resistance was not 
experimentally verified. Second, the use of rats instead of mice meant the physical size of the 
tumors was several‐fold larger than in the mouse (ovarian and mesothelioma) models increasing 
the challenge of achieving nanoparticle penetration and drug delivery to the entire tumor. Third, 
pancreatic cancer is known to be a particularly intractable disease where fibrosis can interfere 
with drug penetration; the results verify both this challenge as well as the need for continued 
development of new strategies and technologies for treating this disease. 
 
NEW eNP‐BASED TREATMENT PARADIGMS 
 
The positive in vivo results described above along with the comprehensive characterization data 
for the eNP prompted us to investigate three new concepts using the eNP technology: (1) in the 
treatment of lymphatic metastatic disease (i.e., regional metastases); (2) as a highly fluorescent 
probe to visually guide surgical resection procedures; and, (3) as a two‐step drug‐delivery device 
for concentrating separately administered drugs at a target site. 
 
eNP‐MEDIATED TREATMENT OF LYMPH NODE METASTASES IN BREAST 
CANCER 
 
In addition to the applications described above, eNPs have also been leveraged to achieve 
lymphatic drug‐delivery in orthotopic models of breast cancer. While breast cancer patients with 
localized disease typically have a favorable long‐term prognosis, occult metastases in the axillary 
(i.e., draining) lymph nodes of patients undergoing radical mastectomy result in a significant 
incidence (18%) of subsequent tumor growth within the lymph nodes following surgery.61 Due to 
the rapid clearance of systemically administered Taxol (half‐life of <6 h), PTX concentrations 
within the regional lymph nodes are sub‐therapeutic and this results in ineffective treatment of 
occult disease. We hypothesized that the eNP‐delivery system could improve the treatment of 
lymphatic disease by leveraging their small diameter (30–50 nm) to traffic within the lymphatic 
channels and deliver a ‘nano‐bolus’ of drug to microscopic disease within the lymph node. 
 
To evaluate eNP trafficking to lymph nodes, fluorescently labeled particles were injected in the 
mammary fat pad of nude mice and the lymph nodes resected and imaged 4 days later. Rho‐eNPs 
appear throughout the sinusoidal spaces where micrometastases are frequently described 
(Figure 8(a)).62 In a large animal pig model, similar lymphatic trafficking was observed over a 
much larger and clinically relevant distance of >40 cm (Figure 8(b)). To confirm that PTX is 
maintained within the eNPs during lymphatic trafficking and delivered to the lymph nodes in 
tumor‐bearing animals, animals bearing 2‐week‐old, orthotopic MDA‐MB‐231 breast cancer 
xenografts received peritumoral injections of Oregon Green‐labeled paclitaxel (PTX‐OG)‐loaded 
Rho‐eNPs. Histological analysis of the lymph nodes 10 days post‐eNP injection revealed the 
presence of PTX‐OG co‐localized with Rho‐eNPs within the lymph nodes demonstrating that 
both the drug and the eNP‐delivery system were present within the lymph node 
(Figure 8(c)).62 The study was repeated with unlabeled PTX‐eNPs and a control injection of 
Taxol and the PTX concentration in the tissue was quantified by HPLC. PTX‐eNPs delivered 
~10‐fold greater concentrations of PTX to the lymph nodes than did Taxol (Figure 8(d)). To 
evaluate whether increasing local concentrations of PTX within the lymphatic tissue would result 
in decreased lymph node metastases, animals bearing 1 week‐old MDA‐MB‐231 xenografts 
were treated with injections of: peritumoral PTX‐eNPs (experimental; 4 mg/kg), peritumoral 
Taxol (local clinical formulation control; 4 mg/kg), intraperitoneal Taxol (systemic clinical 
formulation control; 12 mg/kg) or local unloaded‐eNPs (vehicle/no‐PTX control). Five weeks 
later, animals were sacrificed, lymph nodes harvested, and the presence of disease evaluated via 
bioluminescence imaging of the lymph nodes. Treatment with PTX‐eNPs significantly decreased 
the incidence of lymphatic metastases compared to the unloaded‐eNP control (33% versus 100%, 
respectively) (Figure 8(e)).62 In contrast, while local and systemic Taxol treatments showed a 
trend toward decreased lymphatic disease, neither decrease was significant compared to the 
control. These data demonstrate that PTX‐eNPs migrate directly via the lymphatics to the 
regional draining lymph nodes, which are at greatest risk of metastasis, without the need for 
targeting ligands/antibodies and deliver a therapeutic dose of PTX that decreased the incidence 
of metastatic disease. This was the first study to establish the superiority of nanoparticle‐
mediated delivery compared to Taxol in the treatment of occult nodal disease and encourages 
further development of such technologies toward the clinic. 
 
FIGURE 8 IS OMITTED FROM THIS FORMATTED DOCUMENT 
Figure 8. (a) Rhodamine‐labelled expansile nanoparticle (Rho‐eNPs; red) localize to the 
sinusoidal spaces within lymph nodes (blue = nuclei). (b) eNPs loaded with a near‐infrared dye 
(green) and subcutaneously injected into the mammary fat of a pig traffic over 40 cm to the 
draining lymph node. (c) Confocal microscopy of the sentinel (i.e., draining) lymph node from 
mice receiving injections of Rho‐eNPs loaded with Oregon Green‐labelled paclitaxel (PTX‐OG) 
demonstrate co‐localization of PTX and eNP within the lymph node. (d) PTX‐eNPs deliver 10‐
fold more PTX to the lymph nodes following a subcutaneous injection in the mammary fat pad 
than is achieved with Taxol. (e) PTX‐eNPs significantly reduce the incidence of lymphatic 
disease in an orthotopic model of breast cancer. Taxol does not significantly decrease lymphatic 
disease compared to the control. (Reprinted with permission from Ref 62, Copyright 2013 
Elsevier B.V.) 
 
eNPs AS VISUAL ASSISTS FOR CYTOREDUCTIVE SURGERY 
 
Given the in vivo results of eNP tumor localization, we investigated whether the eNP technology 
could be used as a visual assist for cytoreductive surgery. We therefore developed a highly 
fluorescent rhodamine‐labeled eNP (HFR‐eNP) with the goal of increasing the visibility of 
small, sub‐cm and sub‐mm, tumors to enable complete resections. By using a UV‐active 
fluorophore (rhodamine), we ensured the system would be compatible with inexpensive hand‐
held UV‐lamps available for clinical use in operating suites thereby averting the need for 
expensive near‐infrared, computed tomography (CT), or magnetic resonance (MR) imaging 
technologies. By titering the quantity of rhodamine incorporated into the eNP, we achieved an 
optimum balance between relative fluorescence (i.e., photons/mg of rhodamine; which was 
maximized at lower rhodamine incorporations) and absolute fluorescence (i.e., photons/mL of 
eNPs; which was maximized at higher rhodamine incorporations) with a 0.2% wt/wt 
rhodamine/polymer eNP formulation (Figure 9(a) and (b)).45 Of note, the fluorescence of the 
Rho‐eNPs exceeded that of an equivalent concentration of ‘free’ rhodamine in solution by 10‐ to 
100‐fold indicating that the hydrophobic, conformationally constrained environment of the eNP 
provided a favorable milieu for optimizing the fluorophore's output. 
 
FIGURE 9 IS OMITTED FROM THIS FORMATTED DOCUMENT 
Figure 9. (a) Rhodamine fluorescence as a function of incorporation into expansile nanoparticle 
(eNPs) is optimized in the 0.02% and 0.2% formulations. (b) Rhodamine fluorescence as a 
function of polymer concentration is optimized in the 0.2% formulation. (c) Highly fluorescent 
rhodamine‐labelled eNPs (HFR‐eNPs) visually identify tumors (orange in UV light) during 
cytoreductive surgery. (d) Large, small sub‐cm and microscopic sub‐mm tumors labelled with 
highly fluorescent rhodamine‐labeled eNP (HFR‐eNPs) are visualized post‐resection. (Reprinted 
with permission from Ref 45. Copyright 2016 American Chemical Society) 
 
To evaluate the accuracy of HFR‐eNP localization to tumors, we employed a similar in 
vivomodel of pancreatic carcinomatosis to that described previously.38 Specifically, animals 
bearing 3‐week‐old xenografts received intraperitoneal injections of HFR‐eNPs and were 
euthanized 24 h later with all major organs and tumors harvested and evaluated for the presence 
of HFR‐eNPs. Comparing HFR‐eNP identification of tumors to the gold‐standard, histological 
identification of tumors, it was found that HRF‐eNPs possess a specificity of 99%, a sensitivity 
of 92%, and an overall accuracy of 95%.45 HFR‐eNPs were neither grossly nor histologically 
evident in any major organs including the heart, lungs, brain, liver, spleen, pancreas, stomach, 
intestines, or kidneys. In a follow‐up study, HFR‐eNPs were employed as visual assists during 
cytoreductive surgery. Complete resection of the HRF‐eNP‐marked sub‐cm and sub‐mm tissues 
(Figure 9(c)) was achieved in situ demonstrating the feasibility of using this technology as a 
visual‐guide for cytoreductive surgery (Figure 9(d)).45 
 
TWO‐STEP DELIVERY USING eNPS 
 
Finally, we leveraged the unique structural and responsive characteristics of the eNP to develop 
it as a ‘two‐step’ drug‐delivery device. The idea of a two‐step strategy was first developed by 
Press et al., who employed high‐affinity antibodies (i.e., biotin‐avidin) to achieve in 
vivo localization of a targeting moiety (e.g., tumor‐specific Ab conjugated to avidin) with a 
subsequently administered therapeutic (e.g., radiolabeled‐biotin).63, 64 Unlike the traditional drug‐
loaded, PTX‐eNP approach described above, where PTX and eNP are administered as a single 
unit, the two‐step eNP‐delivery paradigm ‘pre‐treats’ the tumor with unloaded‐eNPs and allows 
sufficient time for the eNPs to localize to the target tissue (i.e., tumor). Subsequently, free PTX 
is administered via a separate injection and accumulates both within the eNP and the nearby 
tumor tissue (i.e., eNP + PTX; Figure 10(a)). While several variations on the two‐step theme 
involving nanoparticles or other antibody‐based systems have been developed,66-70 the 
eNP + PTX two‐step‐delivery method was the first to leverage entirely non‐specific 
hydrophobic–hydrophobic interactions to achieve the in vivo co‐localization of the two 
components of the two‐step system. 
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Figure 10. (a) Schematic of the two‐step paradigm. (b) Paclitaxel (PTX) partitions into swollen 
expansile nanoparticle (eNPs) from an aqueous sink; partitioning is significantly reduced when 
the hydrophobicity of the polymer is reduced. (c) The core of swollen eNPs affords a similarly 
hydrophobic environment compared to ethyl acetate. (d) A pre‐treatment of eNPs significantly 
increases the intracellular concentration of PTX compared to pre‐treatment with media or 
poly(lactic‐co‐glycolic) acid nanoparticles (PLGA‐NPs). (e) Pre‐treatment of established 
intraperitoneal mesothelioma tumors prior to administration of Taxol results in significantly 
increased (~10‐fold) intratumoral concentrations of PTX compared to pre‐treatment with media 
(i.e., Taxol alone) or pre‐treatment with PLGA‐NPs. (Reprinted with permission from Ref 65. 
Copyright 2016 Nature Publishing Group) 
 
To characterize the two‐step delivery strategy, several in vitro and in vivo assays were employed. 
First, a partitioning study was conducted in which swollen eNPs were exposed to an aqueous 
sink of PTX for 24 h and PTX quantified in both the aqueous and eNP phases. PTX partitioned 
from the aqueous sink and into the swollen eNPs in a >4:1 ratio (Figure 10(b)).65 Partitioning is 
thought to occur because the polymer chains of the swollen eNP provide a more hydrophobic 
environment, of similar polarity index to ethyl acetate, than the surrounding aqueous sink 
(Figure 10(c)). As a control, the experiment was also conducted with eNPs that possess more 
hydrophilic succinic acid moieties upon deprotection. These succinic acid‐based eNPs resulted in 
reduced PTX partitioning from the aqueous sink (2:1 ratio) confirming that the hydrophobicity of 
the swollen eNP is one of the major drivers of PTX partitioning. 
 
Second, MSTO‐211H tumor cells were cultured in vitro and treated with either media or media 
containing unloaded‐eNPs. Two days later, the media was exchanged with media containing 
PTX‐labeled with Oregon Green (PTX‐OG). After 4 h, the cells were washed, lysed, and the 
concentration of PTX‐OG compared between treatments. Similar to the partitioning study, PTX‐
OG partitioned into the cells pre‐treated with eNPs at a ratio of >4:1 compared to media pre‐
treated cells (Figure 10(d)).65 PLGA‐NPs were also evaluated in this assay to provide a non‐
swelling generic nanoparticle control. PTX‐OG partitioning into the PLGA‐NP‐treated cells was 
equivalent to media pre‐treated cells indicating that the swelling functionality and relative 
hydrophobicity of the swollen eNP polymer hydrogel are essential to creating a favorable 
environment into which PTX will partition. Third, the in vitro results were confirmed in vivo by 
treating animals bearing established intraperitoneal mesothelioma tumors with either unloaded‐
eNPs (experimental), PLGA‐NPs (non‐swelling, generic nanoparticle control), or saline (no 
nanoparticle control), followed 2 days later by an intraperitoneal injection of Taxol. Tumors 
were harvested and PTX quantified by HPLC and, as with both in vitro studies, pre‐treatment 
with eNPs resulted in a >4:1 increase in intratumoral PTX concentrations compared to the saline 
control while PLGA‐NPs afforded no increase in tumoral accumulation of PTX 
(Figure 10(e)).65 Comparison of the tumoral PTX concentrations achieved with the eNP +PTX 
two‐step strategy versus the ‘traditional’ PTX‐eNP drug‐loaded strategy reveals that the in 
vivo loading of eNPs with systemically administered PTX is possible, albeit the intratumoral 
PTX concentration is ~100‐fold lower than with the ‘pre‐loaded’ PTX‐eNP formulation. These 
results indicate that the eNP + PTX two‐step method will require further development in order to 
maximize the impact of this approach. Nevertheless, one of the potential advantages of the 
current two‐step system may be clarification and simplification of the FDA regulatory process 
(i.e., two‐step delivery—a ‘device’ with the potential for 510 (k) approval used in concert with 
standard systemic delivery of a chemotherapeutic, versus single component delivery—‘drug‐
device’ combination product) and, therefore, shortened time to the Clinic while still providing 
higher concentrations of drug to the target tissue compared to administration of drug alone. In 
sum, these studies demonstrated a proof‐of‐principle approach to using a partition‐coefficient 
driven strategy to achieve two‐step delivery with an otherwise ‘untargeted’ nanoparticle and 
drug. 
 
FUTURE DIRECTIONS FOR THE eNP TECHNOLOGY 
 
Future development of the eNP technology will involve continuation of some of the above 
efforts as well as engagement in new directions. One area that presents particular promise is in 
the development of eNPs as a ‘platform’ technology for the delivery of poorly water‐soluble 
agents and, in particular, novel natural products. PTX itself stands as the archetypal natural 
product—developed over nearly a half‐century—once its supply and formulation were solved, it 
became the most economically and medically successful chemotherapeutic ever 
used.71, 72 Unfortunately, the success story of PTX is not widely shared. The inability to 
overcome poor water solubility is a challenge rampant in the literature of natural products. In 
fact, challenges in formulating PTX early in clinical trials nearly halted development before its 
promising therapeutic activity could be uncovered. The superiority of the PTX‐eNP formulations 
compared to Taxol (i.e., PTX solubilized in Cremophor EL ethanol) in the studies described 
herein is a testament to the value of eNP‐mediated delivery of natural products. While cytotoxic 
natural products have experienced a resurgence due to the development of antibody‐conjugated 
therapies,73 chemical conjugation is not always possible and, where possible, can be challenging, 
ill‐defined, costly, and time consuming. In contrast, encapsulation within the eNP‐delivery 
system requires only that the agent be hydrophobic. Thus, eNPs may provide a means to 
overcome the most challenging traits of natural products—hydrophobicity and poor water 
solubility—and leverage them to our advantage. Several natural products have shown 
compatibility with the eNP‐delivery system including verticillin A74, 75—a molecule with poor 
water solubility but potent anticancer activity as a single‐agent, the ability to overcome drug 
resistance to traditional chemotherapeutics, and the ability to act as an immune checkpoint 
inhibitor. With these and many other potentially therapeutic compounds at hand, the eNP 
technology is ripe for continued development as a drug‐delivery platform, especially for 
peritoneal oncologic applications. 
 
CONCLUSION 
 
We describe the eNP drug‐delivery technology from its origin and mechanistic characterization 
to its in vivo application as a therapy in peritoneal carcinomatoses, a treatment for lymphatic 
metastases, a fluorescent guide for surgical resections, and a two‐step delivery system. The 
observation that one particle performs so many different roles is a testament to the importance of 
engineering systems with the end, physiological application, in mind. It is also scientifically 
satisfying, as there is nothing more disappointing than a nanoparticle system that only performs 
in one specific, well‐defined scenario. Importantly, the Materials‐Based Targeting affords 
tumor‐specific localization without the need for targeting moieties or antibodies, and this may 
provide a new paradigm by which nanotechnology experts can design future drug‐delivery 
systems. Nanoparticle complexity can be an enticingly elegant academic solution but an 
unwelcome curse for subsequent clinical translation. The lessons learned in this nanoparticle 
case study serve as an example and an inspiration for other researchers to pursue novel 
nanotechnology advances for the treatment of cancer. It has been 11 years since the FDA‐
approved Abraxane,76-81 yet significant opportunities remain and much work has yet to be done 
to fulfill the promise of nanotechnology to provide innovative platform solutions for the unmet 
cancer needs in human health care. 
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